Frontage (HKG:1521) recorded a net profit of $0.2 million for the nine months ended Sept. 30, lower than the $9.8 million net profit logged for the corresponding period last year, a Tuesday filing with the Hong Kong Exchange said.
The laboratory and related services provider's revenue for the nine months was $191.1 million, 3.6% lower than HK$XX billion booked a year ago.
The detailed financial results of the company are disclosed in the unaudited third-quarter results for 2024 of the company's controlling shareholder, Hangzhou Tigermed Consulting (HKG: 3347, SHE:300347).
The company's shares were down over 1% on Tuesday's close.
Price (HKD): $0.73, Change: $-0.010, Percent Change: -1.35%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。